Table 5.

Adjusted odds ratios (OR) and 95% confidence intervals (CI) of the presence of hyperuricemia associated with the visceral adiposity index, along with metabolic health and obesity phenotypes stratified by age groups.

	ATP-III criteria		HOMA criteria
	Below 65 years	Above 65 years	Below 65 years	Above 65 years
Visceral adiposity index
1st Quartile	1 (Ref)	1 (Ref)	1 (Ref)	1 (Ref)
2nd Quartile	1.36 (1.07–1.73)	1.09 (0.74–1.62)	1.35 (1.07–1.72)	1.1 (0.74–1.63)
3rd Quartile	2.05 (1.62–2.6)	1.07 (0.71–1.62)	2.13 (1.69–2.67)	1.16 (0.78–1.72)
4th Quartile	4.99 (3.84–6.49)	2.78 (1.77–4.39)	5.78 (4.61–7.23)	3.35 (2.25–4.98)
Obesity phenotype
MHNO	1 (Ref)	1 (Ref)	1 (Ref)	1 (Ref)
MUNO	1.29 (1.03–1.61)	1.32 (0.9–1.95)	1.64 (1.31–2.04)	1.24 (0.84–1.85)
MHO	1.1 (0.86–1.41)	1.22 (0.73–2.04)	1.17 (0.97–1.41)	1.21 (0.83–1.77)
MUO	1.71 (1.33–2.18)	2.35 (1.5–3.67)	1.93 (1.53–2.43)	2.71 (1.76–4.18)

Abbreviations: ATP-III, the Adult Treatment P anel-III; HOMA, homeostasis model assessment of insulin resistance; MHNO, metabolically healthy non-obese; MUNO, metabolically unhealthy non-obese; MHO, metabolically healthy obese; and MUO, metabolically unhealthy obese. Model was adjusted for age, sex, urban/rural resident, smoking status, alcohol status, metabolic health-obesity phenotypes, white blood cell, total cholesterol, blood pressure, glucose and hs-CR.